Skip to main content

Showing 5 matches for the following: Inventor: "Li, Chuan-Yuan" ×

Method to enable cancer immune checkpoint therapy

Method to enable cancer immune checkpoint therapy

Unmet Need Cancer remains to be a heavy burden on Americans as many current gold-standard treatments can be ineffective. In 2022, an estimated 623,000 Americans were living with metastatic cancer and is predicted to increase…

Read More

A genomics-based method to identify cancer patients that will benefit from immune checkpoint therapy

A genomics-based method to identify cancer patients that will benefit from immune checkpoint therapy

Unmet Need Non-small-cell lung cancer accounts for 82% of all lung cancer diagnoses. Immune checkpoint blockade treatment is an exciting new course of action among advanced stage non-small-cell lung cancer patients. However, only a minority…

Read More

Method to sensitize cancer radiotherapy and chemotherapy

Method to sensitize cancer radiotherapy and chemotherapy

Unmet Need While radiotherapy and/or chemotherapy are used for >90% of cancer patients in clinical settings, the therapeutic outcomes are far from ideal for many types of tumors due to the development of drug resistance…

Read More

Improving immune checkpoint blockade therapy by inhibiting ATM protein

Improving immune checkpoint blockade therapy by inhibiting ATM protein

Unmet Need The great enthusiasm for immune checkpoint blockade (ICB) therapy is justified by the spectacular, durable successes it has had in some previously difficult to treat cancers such as melanoma and lung cancer. However,…

Read More

Improving immune checkpoint therapies for cancer by inhibiting the PCSK9 protein

Improving immune checkpoint therapies for cancer by inhibiting the PCSK9 protein

Value Proposition Immune checkpoint inhibitor therapies are exciting new drugs for treatment of cancers. Despite their efficacy for certain cancers, immune checkpoint inhibitors only effective in 10-30% of cancer patients. Because of this, there is…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us